Skip to main content

Table 1 Five-point grading scale of adverse events

From: Study protocol: a randomized, double-blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations

1 = mild

Discomfort noticed but no disruption of normal daily activity

2 = moderate

Discomfort sufficient to reduce or affect daily activity

3 = severe

Inability to work or perform normal daily activity

4 = life threatening/disabling

Represents an immediate threat to life

5 = death

Related to adverse event

Back to article page

Pilot and Feasibility Studies

ISSN: 2055-5784